Melatonin in sleep disorders
Por:
Poza JJ, Pujol M, Ortega-Albás JJ and Romero O
Publicada:
1 sep 2022
Ahead of Print:
1 ago 2022
Resumen:
Melatonin is the main hormone involved in the control of the sleep-wake cycle. It is easily synthesisable and can be administered orally, which has led to interest in its use as a treatment for insomnia. Moreover, as production of the hormone decreases with age, in inverse correlation with the frequency of poor sleep quality, it has been suggested that melatonin deficit is at least partly responsible for sleep disorders. Treating this age-related deficit would therefore appear to be a natural way of restoring sleep quality, which is lost as patients age. However, despite the undeniable theoretical appeal of this approach to insomnia, little scientific evidence is available that supports any benefit of this substitutive therapy. Furthermore, the most suitable dose ranges and pharmaceutical preparations for melatonin administration are yet to be clearly defined. This review addresses the physiology of melatonin, the different pharmaceutical preparations, and data on its clinical usefulness. (C) 2018 Sociedad Espanola de Neurologia. Published by Elsevier Espana, S.L.U.
Filiaciones:
Poza JJ:
Servicio de Neurología, Hospital Universitario Donostia, San Sebastián, España
Pujol M:
Unidad Multidisciplinar de Sueño, Hospital Universitario de Santa María, Lleida, España
:
Unidad de Sueño, Hospital General Universitario de Castellón, Castellón, España
Romero O:
Unidad Multidisciplinar de Sueño, Hospital Universitario Vall d´Hebron, Barcelona, España
gold
|